Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), Incyte (INCY) and Radnet (RDNT)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ascendis Pharma (ASND – Research Report), Incyte (INCY – Research Report) and Radnet (RDNT – Research Report) with bullish sentiments.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ascendis Pharma (ASND)
Barclays analyst Eliana Merle maintained a Buy rating on Ascendis Pharma today and set a price target of $342.00. The company’s shares closed last Monday at $242.09.
According to TipRanks.com, Merle is a 3-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ascendis Pharma with a $287.42 average price target, a 22.2% upside from current levels. In a report issued on February 17, Morgan Stanley also maintained a Buy rating on the stock with a $256.00 price target.
See today’s best-performing stocks on TipRanks >>
Incyte (INCY)
In a report released today, Etzer Darout from Barclays maintained a Buy rating on Incyte, with a price target of $117.00. The company’s shares closed last Monday at $100.04.
According to TipRanks.com, Darout is a 5-star analyst with an average return of
Incyte has an analyst consensus of Moderate Buy, with a price target consensus of $109.20.
Radnet (RDNT)
In a report released today, Andrew Mok CFA from Barclays maintained a Buy rating on Radnet, with a price target of $86.00. The company’s shares closed last Monday at $75.22.
According to TipRanks.com, CFA is a 1-star analyst with an average return of
Currently, the analyst consensus on Radnet is a Strong Buy with an average price target of $90.80.
